Design
Editorial
Authors
Loading...
Highlights the danger of polypharmacy and drug-drug interactions when applying disease-specific guidelines to patients with multimorbidity.
Key points are not available for this paper at this time.
Marengoni et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: